Integra LifeSciences For 3Q23 Expects Revenues Of $386M-$390M Vs. Consensus Of $388.59M; Adjusted EPS Of $0.76-$0.80 Vs. Consensus Of $0.84
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences expects 3Q23 revenues to be in the range of $386M-$390M, slightly below the consensus of $388.59M. The company also anticipates adjusted EPS to be between $0.76-$0.80, lower than the consensus of $0.84. The forecast includes the impact of the Boston recall.
July 27, 2023 | 4:40 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Integra LifeSciences' lower-than-expected 3Q23 revenue and EPS forecasts may negatively impact its stock price in the short term.
Integra LifeSciences' 3Q23 revenue and EPS forecasts are slightly below the consensus estimates. This could lead to a negative sentiment among investors, potentially causing a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100